Efficacy and Safety of TenoMiR in Lateral Epicondylitis (NCT06192927) | Clinical Trial Compass
CompletedPhase 2
Efficacy and Safety of TenoMiR in Lateral Epicondylitis
United States, United Kingdom123 participantsStarted 2024-04-10
Plain-language summary
This study is testing a drug called TenoMiR that is being developed for the treatment of tennis elbow (lateral epicondylitis). The study drug is a new compound that works by improving the quality of the collagen which helps repair damage to the elbow. The study drug is being developed in the hope of providing a more reliable treatment than those currently available and can be given at the time of first diagnosis, so that recovery can begin as soon as possible. The study drug has been tested in humans in an earlier study, and appeared to be safe and well-tolerated. This study aims to test the study drug in a larger number of participants.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subject has a clinical diagnosis of lateral epicondylitis.
✓. Aside from lateral epicondylitis, the subject is otherwise healthy as determined by a responsible physician, based on medical history, physical examinations, concomitant medication, vital signs, 12-lead ECGs and clinical laboratory evaluations. Laboratory values may be retested once at the discretion of the Investigator.
✓. Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion (as confirmed by tenderness at lateral epicondyle and positive pick up back of chair sign).
✓. Subject's symptoms have persisted for at least 6 weeks to 9 months, despite conservative treatment that includes 1 or combinations of:
✓. Physical therapy
✓. Splinting
✓. NSAIDs
Exclusion criteria
✕. Subject has undergone previous corticosteroid injection therapy to the affected elbow in less than 6 months prior to enrolment.
What they're measuring
1
Numeric Rating Scale (NRS) pain score. Minimum score 0 (no pain), Maximum score 10 (worst possible pain)
. Subjects unwilling or unable to discontinue use of pain medication (opiate or NSAID) from at least 1 week prior to Investigational Medicinal Product (IMP) administration.
✕. Subject has received previous Platelet-Rich Plasma (PRP) injection to the affected elbow.
✕. Subject uses or has recent use of medications known to affect the skeleton (e.g., glucocorticoid usage \>5 mg/day, fluoroquinolone antibiotics).
✕. Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis.